Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer

Human epidermal growth factor receptor 2 (ErbB2) is an attractive therapeutic target for metastatic breast cancer. The kinase has been clinically observed to harbor a gatekeeper mutation T798M in its active site, which causes acquired resistance to the first-line targeted breast cancer therapy with small-molecule tyrosine kinase inhibitors. Previously, several theories have been proposed to explain the molecular mechanism of gatekeeper mutation-caused drug resistance, such as blocking of inhibitor binding and increasing of ATP affinity. In the current study, the direct binding of three wild type-selective inhibitors (Lapatinib, AEE788 and TAK-285) and two wild type-sparing inhibitors (Staurosporine and Bosutinib) to the wild-type ErbB2 and its T798M mutant are investigated in detail by using rigorous computational analysis and binding affinity assay. Substitution of the polar threonine with a bulky methionine at residue 798 can impair and improve the direct binding affinity of wild type-selective and wild type-sparing inhibitors, respectively. Hindrance effect is responsible for the affinity decrease of wild type-selective inhibitors, while additional nonbonded interactions contribute to the affinity increase of wild type-sparing inhibitors, thus conferring selectivity to the inhibitors for mutant over wild type. The binding affinity of Staurosporine and Bosutinib to ErbB2 kinase domain is improved by 11.9-fold and 2.1-fold upon T798M mutation, respectively. Structural analysis reveals that a nonbonded network of S-π contact interactions (for Staurosporine) or an S-involving halogen bond (for Bosutinib) forms with the sulfide group of mutant Met798 residue.

[1]  P. Zhou,et al.  Mutatomics analysis of the systematic thermostability profile of Bacillus subtilis lipase A , 2014, Journal of Molecular Modeling.

[2]  M. Eck,et al.  Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. , 2010, Biochimica et biophysica acta.

[3]  Peng Zhou,et al.  Fast and reliable prediction of domain-peptide binding affinity using coarse-grained structure models , 2013, Biosyst..

[4]  Mindy I. Davis,et al.  Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.

[5]  Chao Yang,et al.  What are the ideal properties for functional food peptides with antihypertensive effect? A computational peptidology approach. , 2013, Food chemistry.

[6]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[7]  J. Engelman,et al.  Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2 , 2013, Clinical Cancer Research.

[8]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[9]  Leming Shi,et al.  Molecular docking to identify associations between drugs and class I human leukocyte antigens for predicting idiosyncratic drug reactions. , 2015, Combinatorial chemistry & high throughput screening.

[10]  Haidong Wang,et al.  A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity , 2014, Amino Acids.

[11]  Jing Zhao,et al.  Breast Cancer: Epidemiology and Etiology , 2014, Cell Biochemistry and Biophysics.

[12]  Tong Wang,et al.  Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer , 2016, Molecular informatics.

[13]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[14]  Jian Huang,et al.  Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis , 2016, Journal of biomolecular structure & dynamics.

[15]  B. Kocić,et al.  Current and future anti-HER2 therapy in breast cancer. , 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[16]  Peng Zhou,et al.  Indirect Readout in Protein-Peptide Recognition: A Different Story from Classical Biomolecular Recognition , 2014, J. Chem. Inf. Model..

[17]  P. Jänne.  Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours. , 2008, Lung cancer.

[18]  Yan Zhao,et al.  Revisiting the molecular mechanism of acquired resistance to reversible tyrosine kinase inhibitors caused by EGFR gatekeeper T790M mutation in non-small-cell lung cancer , 2018, Medicinal Chemistry Research.

[19]  Carlos L Arteaga,et al.  Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. , 2012, Critical reviews in oncogenesis.

[20]  Yanrong Ren,et al.  Gaussian process: a promising approach for the modeling and prediction of Peptide binding affinity to MHC proteins. , 2011, Protein and peptide letters.

[21]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[22]  Jian Huang,et al.  Structural and energetic insights into the intermolecular interaction among human leukocyte antigens, clinical hypersensitive drugs and antigenic peptides , 2015 .

[23]  Peng Zhou,et al.  Characterization of PDZ domain–peptide interactions using an integrated protocol of QM/MM, PB/SA, and CFEA analyses , 2011, J. Comput. Aided Mol. Des..

[24]  Tao Xu,et al.  Structure-based grafting and identification of kinase-inhibitors to target mTOR signaling pathway as potential therapeutics for glioblastoma , 2015, Comput. Biol. Chem..

[25]  P. Zhou,et al.  Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands , 2018, Artificial cells, nanomedicine, and biotechnology.

[26]  Monilola A. Olayioye,et al.  Update on HER-2 as a target for cancer therapy: Intracellular signaling pathways of ErbB2/HER-2 and family members , 2001, Breast Cancer Research.

[27]  S. Boxer,et al.  Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain , 2012, PloS one.

[28]  Jian Huang,et al.  A two-step binding mechanism for the self-binding peptide recognition of target domains. , 2016, Molecular bioSystems.

[29]  B. Luke,et al.  Can structural features of kinase receptors provide clues on selectivity and inhibition? A molecular modeling study. , 2015, Journal of molecular graphics & modelling.

[30]  Ya-wei Wang,et al.  Integrated Exploitation of the Structural Diversity Space of Chemotherapy Drugs to Selectively Inhibit HER2 T798M Mutant in Lung Cancer , 2017, Chemistry & biodiversity.

[31]  Chao Yang,et al.  Biomacromolecular quantitative structure–activity relationship (BioQSAR): a proof-of-concept study on the modeling, prediction and interpretation of protein–protein binding affinity , 2013, Journal of Computer-Aided Molecular Design.

[32]  S. F. Boys,et al.  The calculation of small molecular interactions by the differences of separate total energies. Some procedures with reduced errors , 1970 .

[33]  Roland L. Dunbrack,et al.  proteins STRUCTURE O FUNCTION O BIOINFORMATICS Improved prediction of protein side-chain conformations with SCWRL4 , 2022 .

[34]  R. Roskoski.  Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. , 2016, Pharmacological research.

[35]  Peng Zhou,et al.  Targeting Self-Binding Peptides as a Novel Strategy To Regulate Protein Activity and Function: A Case Study on the Proto-oncogene Tyrosine Protein Kinase c-Src , 2017, J. Chem. Inf. Model..

[36]  A. Bondi.  van der Waals Volumes and Radii , 1964 .

[37]  R. O'Regan,et al.  The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy , 2012, Chemotherapy research and practice.

[38]  Walter Thiel,et al.  QM/MM methods for biomolecular systems. , 2009, Angewandte Chemie.

[39]  Nikolas von Bubnoff,et al.  Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib , 2011, PloS one.

[40]  Yan Shen,et al.  Analysis of different HER‐2 mutations in breast cancer progression and drug resistance , 2015, Journal of cellular and molecular medicine.

[41]  Chao Yang,et al.  Self-Binding Peptides: Folding or Binding? , 2015, J. Chem. Inf. Model..

[42]  W. Herrebout,et al.  Halogen bonding to a divalent sulfur atom: an experimental study of the interactions of CF3X (X = Cl, Br, I) with dimethyl sulfide. , 2011, Physical chemistry chemical physics : PCCP.

[43]  R. Friedman,et al.  The molecular mechanism behind resistance of the kinase FLT3 to the inhibitor quizartinib , 2017, Proteins.

[44]  Tingjun Hou,et al.  Insight into Crizotinib Resistance Mechanisms Caused by Three Mutations in ALK Tyrosine Kinase using Free Energy Calculation Approaches , 2013, J. Chem. Inf. Model..

[45]  L. Królicki,et al.  Synthesis, physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer. , 2014, European journal of medicinal chemistry.

[46]  Feng-Huei Lin,et al.  Quantitative Analysis of Ligand-EGFR Interactions: A Platform for Screening Targeting Molecules , 2015, PloS one.

[47]  Xianfeng Ding,et al.  Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer , 2015, Amino Acids.